Clinical Trial Update: Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating imatinib for chromosome abnormalities in chronic myeloid leukemia and for gastrointestinal stromal tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib (Gleevec/Glivec) (Imatinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors | Phase 4 | Status: TERMINATED